Eli Lilly announced on July 16 that it has reached a final agreement to acquire clinical-stage biopharmaceutical company AtaiBeckley for $6.75 per share in cash, with a trading equity value of approximately US$2.8 billion. Additionally, if its two candidate treatments for mental illness reach specific R&D and regulatory milestones, shareholders can also receive up to $2.50 or worth of equity per share, corresponding to a potential additional equity value of approximately $1 billion. AtaiBeckley focuses on the development of innovative treatments for mental illness. Its core product, BPL-003, is a nasal spray 5-meo-DMT preparation for treating intractable depression. It has been recognized as a breakthrough therapy by the US FDA and phase III clinical preparations have begun; another candidate product, VLS-01, is currently in phase IIb clinical trials. The transaction is expected to close in the third quarter of this year and is still subject to shareholder and regulatory approval.

Eli Lilly announced on July 16 that it has reached a final agreement to acquire clinical-stage biopharmaceutical company AtaiBeckley for $6.75 per share in cash, with a trading equity value of approximately US$2.8 billion. Additionally, if its two candidate treatments for mental illness reach specific R&D and regulatory milestones, shareholders can also receive up to $2.50 or worth of equity per share, corresponding to a potential additional equity value of approximately $1 billion. AtaiBeckley focuses on the development of innovative treatments for mental illness. Its core product, BPL-003, is a nasal spray 5-meo-DMT preparation for treating intractable depression. It has been recognized as a breakthrough therapy by the US FDA and phase III clinical preparations have begun; another candidate product, VLS-01, is currently in phase IIb clinical trials. The transaction is expected to close in the third quarter of this year and is still subject to shareholder and regulatory approval.